Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?

导出原文传递

翻译打印收藏纠错

作者： Othman,Al-Sawaf ^[1] ; John F,Seymour ^[2] ; Arnon P,Kater ^[3] ; Kirsten,Fischer ^[1]

作者单位： Department of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University Hospital, German CLL Study Group, Gleueler Strasse 176, 50935 Cologne, Germany. ^[1] Department of Hematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, 305 Grattan Street, Melbourne, Victoria 3000, Australia. ^[2] Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Research Center Amsterdam (LYMMCARE), Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: a.p.kater@amsterdamumc.nl. ^[3]

关键词 CLL Chemoimmunotherapy Chronic lymphocytic leukemia Fixed-duration therapy MRD Minimal residual disease Targeted agents

主题词人类(Humans);白血病, 淋巴细胞, 慢性, B细胞(Leukemia, Lymphocytic, Chronic, B-Cell);肿瘤, 残余(Neoplasm, Residual);治疗结果(Treatment Outcome)

DOI 10.1016/j.hoc.2021.03.007

PMID 34102145

发布时间 2022-03-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交